Asia’s Largest Web3 Event TOKEN2049 Exclusively Unveils NFT Assets Valued Over US$100 Million
22.9.2022 04:40:00 EEST | Business Wire | Press release
TOKEN2049, Asia’s premier crypto conference, announced that it will be showcasing a first-of-its-kind, immersive NFT experience, entitled the OP3N WHALE NFT Exhibition, at its upcoming Singapore edition from 28 to 29 September. The exhibition will be presenting NFT assets with a market value exceeding US$100 million — the first time such a collection owned by a single entity has ever been on display to the public.
The exhibition was developed by OP3N, a launchpad for IP and communities in Web3, and WHALE, the omni-versal membership club with a treasury that includes the world’s largest collection of rare, high-value NFTs spanning gaming, art, and virtual real estate.
Raphael Strauch, Founder of TOKEN2049 said: “Today’s Web3 ecosystem reflects the exciting creativity and innovation being brought by a myriad of industries by way of their growing interest in NFTs — and so much of this is taking place in Asia. We have an exciting programme for our attendees — and this exhibition is just one part.”
Showcasing creatives, brands, and curators from the region that exemplify the global dynamic of East Meets West, the exhibition will make its exclusive debut at Asia’s largest Web3 event and TOKEN2049’s largest-ever conference in its history. An estimated 7,000 visitors are expected to attend.
The exhibition includes artworks by renowned digital artist Pak, famed for spearheading Sotheby’s first-ever NFT sale; leading glitch artist XCOPY; Milanese artist duo Hackatao; and award-winning Asian-American photographer Michael Yamashita.
TOKEN2049 Singapore will also feature a rotating display of generative art masterpieces from New York City’s Museum of Modern Art (MoMA)’s permanent collection artist Brendan Dawes and Instagram photography sensation Ryosuke Kosuge. These works will be displayed at WHALE’s solo booth at the conference.
Renowned NFT collector and WHALE founder WhaleShark, said: “Non Fungible technology has ignited a global digital renaissance of art and culture, and the ability to partner with TOKEN2049 and OP3N to showcase some of the earliest and most renowned pioneers of this sector is truly an honor. The exhibition puts the spotlight on this inevitable revolution of the arts with a focus on a time-tested creative industry rather than the flavor of the month.”
In addition, attendees will be able to see OP3N’s latest NFT drop “A3”, developed by YOON and VERBAL who are behind the iconic Tokyo-based fashion brand AMBUSH®. The iconic phygital “A3” NFT will be uniquely presented in a glass display case on the exhibition floor.
“Art, culture and technology are intersecting in exciting and completely new ways, with many industry firsts taking place around the globe,” said Jaeson Ma, Co-Chief Executive Officer and Founder of OP3N, the world’s preeminent contemporary NFT experience brand. “From digital creators and traditional artists to fashion brands such as AMBUSH who’s been expanding their presence in the NFT space, we’re bringing together an incredible pool of talent to celebrate and honor their work.”
Jaeson will also be speaking on a panel on ‘The Future of IP & Communities in Web3’ on 29 September at 2:45 PM along with VERBAL who will speak more about “A3” in detail.
TOKEN2049 Singapore’s agenda will be featuring a series of discussions touching on the latest developments in the Web3 ecosystem — from the global macro narrative for crypto, the rise of Web3 gaming, the emerging social and creator economy, the future of AI and generative art, present and future Web3 infrastructure, and many more.
As part of Asia Crypto Week, TOKEN2049 attendees can expect to attend a full line-up of side events, conferences, networking events, workshops, and parties taking place throughout the week.
For more information and continued updates on TOKEN2049 Singapore, please visit: https://www.asia.token2049.com/.
About TOKEN2049
TOKEN2049 is a premier Web3 event, organized annually in Singapore and London, where decision-makers in the global crypto ecosystem connect to exchange ideas, network and shape the industry. TOKEN2049 is a global meeting place for entrepreneurs, institutions, industry insiders, investors, and those with a strong interest in the crypto and blockchain industry.
About OP3N
Founded in 2021 as a subsidiary of EST Media Holdings, OP3N imagines a world where Communities can come together to create, own, and bring their ideas to the world. OP3N’s mission is to be a Launchpad for Ideas and Communities to create meaningful experiences together. By consolidating the tools needed to mint, share and engage with NFTs and digital tokens into one vertical stack, OP3N leverages its cross-industry expertise from the entertainment, gaming and tech ecosystems, to lay the foundations for a new era of community-driven, inclusive entertainment while bringing everyone together on a journey into Web3. For more information, please visit: https://op3n.world/
About WHALE
WHALE is the omni-versal membership club for the natively digital, focused on immersing WHALE Members in the renaissance of digital art and culture. Powered by the club's native social token, $WHALE, and the club treasury, the WHALE Vault, WHALE delivers physical and metaversal content, information, and experiences for a new generation of digital enthusiasts. Established in 2020 by the pseudonymous WhaleShark, WHALE boasts over 25,000 members worldwide, all focused on the longer-term discussion and immersion of Web 3 and the revolution of true digital asset scarcity, ownership, and management.
About AMBUSH®
AMBUSH® began as an experimental jewelry line – innovative pop art-inspired designs capturing a distinct Tokyo aesthetic. With apparel created as a canvas to complete the story, AMBUSH® evolved into designing unisex collections. The brand made its Paris debut in 2015 with YOON & VERBAL being listed as two of Business of Fashion’s Top 500 people influencing the global fashion industry for 5 consecutive years from 2015, and HYPEBEAST 100 list for 8 consecutive years. In 2017 AMBUSH® was selected as one of the top 8 finalists for the LVMH PRIZE. In 2018, AMBUSH® debuted at Amazon Fashion Week Tokyo. In the same year, Kim Jones named YOON as jewelry designer for Dior Men. In 2022, AMBUSH® presented the brand’s first runway at Milan Fashion Week and launched its proprietary metaverse SILVER FCTRY. Its first POW!® NFT collection sold out in minutes, ranking it among the top 10 projects on Opensea, and the second most transacted NFT from Japan at the time of its debut.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220921005455/en/
Contact information
Melissa Esguerra
token2049sg@wachsman.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 15:05:00 EEST | Press release
A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is designed to interpret cardiac MRI scans by connecting moving images of the heart with corresponding clinical radio
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 15:00:00 EEST | Press release
Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The research challenges long-held assumptions about media value, showing that not all impressions are equal. Live sports rem
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 15:00:00 EEST | Press release
Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer cell killing activity,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The Phase 3 study and the enrollment of the first patient with Precem-TcT build on the Company’s more than 20 years of expertise in colorectal cancer, and highlight our commitment to advancing differentiated ADCs for heavily pretreated patients with limited treatment options.” The PROCEADE®-CRC-03 study
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 14:00:00 EEST | Press release
Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early, subtle symptoms. Individuals in this stage, classified as CHR-P, represent a critical pr
SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend21.5.2026 13:30:00 EEST | Press release
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company’s previously declared special cash dividend. The Company previously announced a special cash dividend of US$55.00 per common share, payable to valid holders of the Company’s common shares as of the close of business on May 23, 2025 ET. The Company previously informed shareholders that completed instruction materials were to be submitted prior to December 31, 2025 in order to facilitate receipt of the dividend. The Company has now extended that submission deadline to June 30, 2026. Shareholders and nominee brokers that have not yet submitted their instruction materials are reminded to do so on or before June 30, 2026 in order to facilitate payment of the dividend. If you have any questions regarding the process you need to un
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
